Metabolomics is a recent science that could be defined as the comprehensive qualitative and quantitative analysis of all small molecular weight compounds present in a cell, 
Introduction
Metabolomics is the newest of the "omics" sciences, part of "functional genomics" with genomics, transcriptomics and proteomics ( Figure 1 analysis of all metabolites (= small molecular weight compounds = metabolome) present in a cell, an organ or an organism at a specific time point" [1] . The compounds generally considered as metabolites are molecules with a molecular weight inferior to 2000 Da. It could be primary metabolites such as sugars, amino acids, organic acids, fatty acids, energetic metabolites, nucleotides, urea metabolites,… In plants or microorganisms, secondary metabolites presenting a very huge structural diversity could also be found. A metabolome, and more particularly the human metabolome, consists in a mixt of both endogenous and exogenous compounds [2] . Actually, several thousands of human metabolites have been described and could be accessed freely in the "Human Metabolome Database" which offers detailed informations about around 40 ,000 endogenous and exogenous metabolites [2] . Up to 200 000 metabolites are estimated to occur in the plant kingdom [1] .
The study of metabolites is in reality very old, and saccharose, isolated for the first time, from beets, in 1747 by Marggraf (but its structure only determined at the end of the XIXth Century) could be considered as one of the first metabolite isolated [3] . Even if metabolites are studied in various organisms since numerous years, 'metabolomics' in its actual acceptation is very recent. The first paper that could be considered as a real "metabolomics" analysis is the paper from Arthur B. Robinson and Linus Pauling in 1971, dedicated to the analysis of urine vapour and breath metabolites using gas chromatography. In this paper, 250 metabolites were analysed and identified in breath, and 280 in urine vapour [4] . Nevertheless, the first mention of the term "metabolome" in the literature was only in 1998 (as sorted by bibliographic engines) in a paper of S.
Oliver about the functional analysis of the yeast genome [5] . The word "metabolomics" In 1999, the term "metabonomics" was also introduced by Nicholson and colleagues in a paper where it was defined as "the quantitative measurement of the dynamic multiparametric metabolic response of living systems to physiopathological stimuli or genetic modifications" [6] . Nowadays, the term metabolomic(s) is the most currently used, as it could clearly be seen in Figure  2 . The concept metabonomics is nevertheless still used, particularly for the study of dynamic changes in the metabolome, mainly in the toxicological field. analysis and nutrition [7, 8] (were the techniques are also routinely used by the food industry) to functional genomics applications. More particularly in the pharmaceutical field, metabolomic techniques and applications find scope from drug discovery to clinical development of new medicines. This includes target identification and validation, elucidation of the mechanisms of action of drugs, lead identification [9, 10] , identification of drug efficacy or pathology biomarkers [11] [12] [13] , toxicological analysis by identification of safety biomarkers [14] [15] [16] but also quality control, particularly of medicinal plants [17, 18] and bioactive drug discovery from natural sources [19] .
Recently, several reviews have highlighted the potential of metabolomics in the drug discovery process [20--22] . The challenge in metabolomics is then to find an analytical technique or a technological approach, combined with adequate statistical analysis, that allows the detection and the identification of the highest possible number of metabolites.
Technological approaches
As described above, one of the objectives of metabolomics in the pharmaceutical field is to identify and quantify specific metabolic markers susceptible to improve quality control, improve early diagnosis, survey therapeutic outcomes and facilitate the development of novel drugs candidates [23--25] .
The methodology relies on differential metabolic expression profiling. The fundamental approach is based on the assumption that the pathology of concern or the therapeutic treatment (i.e. drug or drug candidate) will affect some physiological processes causing changes in the metabolic expression levels. Metabolic generating similar signals in both sample groups are ignored while significantly up--and down regulated metabolites become potential biomarkers. Differential expression profiling requires both a sensitive technology to discern any tiny differences and a high throughput system in order to process large series of samples required to reach statistical significance.
Besides "metabolic fingerprinting" that consists in the comparison of metabolic fingerprints, without identification of particular metabolites, there are two general approaches, target specific and global or non--directed, for metabolomic biomarker discovery. Target--specific, or biology driven, approach frequently uses mass spectrometry and is useful for validation and routine clinical analysis. In that case, tested metabolites are typically selected on the basis of current knowledge of disease mechanism and pathophysiology. Global/non--directed approaches may have more potential for biomarker discovery because they are unbiased. They allow the simultaneous evaluation of hundreds to thousands metabolites in a blind manner without a priori increasing the potential number of candidate biomarkers. CE is nowadays a powerful alternative to chromatographic techniques such as GC or HPLC to carry out metabolomic studies. Today CE is increasingly used for several reasons: its high efficacy, versatility and feasibility of incorporating a large number of selectors in the background electrolyte that greatly facilitates method development, rapidity, cheapness (a low consumption of reagents), and minimum environmental impact with respect to HPLC or GC techniques. The high peak efficiency that can be obtained in CE (between 100,000--200,000 plates in a typical capillary) is one of the major advantages [32] .
When a high selectivity and sensitivity is required, ultraviolet detection (UV) is not the preferred detection system. Mass spectrometry (MS) detection offers not only an improvement in the sensitivity but also offers the possibility to unambiguously identify an analyte by its mass to charge ratio (m/z). In addition, when MS/MS experiments are performed, structural information can also be obtained from the fragmentation mass spectrum which offers an excellent selectivity. Given the abundant and ubiquitous presence of 1H in most metabolites, 1D 1 H--NMR spectroscopy is the primary source of NMR--based metabolomics data, used almost exclusively to generate metabolomics data until the recent years. In spite of numerous advantages, which are presented in Table  1 in comparison with MS, the main drawback of metabolite analysis by NMR platforms is the sensitivity that does not match the one of MS based platforms. Nevertheless, the highly reproducible, quantitative results of NMR, the easy sample preparation step required for the method, ensure it will remain extremely valuable in metabolomic studies, especially when combined with MS based techniques [34--36] . NMR is particularly valuable in the natural products area where the method is highly helpful to identify unknown secondary metabolites [37--38] .
Vibrational spectroscopy and more particularly Fourier transform infrared spectroscopy (FT--IR) were found particularly interesting for metabolomic studies due to their rapid, high--throughput and non--destructive analysis of a wide range of sample types. The resultant infrared absorbance spectrum is characteristic of the functional groups within the sample and thus constitutes an unique fingerprint [39] . This is a promising analytical tool for metabolomic studies however, it is important to note that the presence of water in a sample may influence the bands at certain specific wave number and that environmental conditions around the FT--IR instrument can cause variations in the spectra. Moreover a strong expertise in the chemometric analysis of spectra is required.
It is worth noting that an intrinsic disadvantage of in vitro and ex vivo metabolomic experiments is the loss of information regarding the subcellular and cellular localization of the metabolites. Recently, imaging mass spectrometry (IMS) and magnetic resonance imaging (MRI) have been introduced providing information about spatial distribution.
This technique allow spatial mapping of lipids, peptides or drugs in fixed samples, without extraction and loss of cellular architecture. This approach is very promising improving our understanding of cellular physiology and enzyme function [40] .
All those analytical tools provide complementary metabolic information and it is thus recommended to use then in combination.
Other challenges
Recent interest in the field has yielded a large number of candidate biomarkers in various diseases. However, the small size and poor design of some studies drove validation of these biomarkers quite challenging [41] . Critical steps that should be undertaken to avoid any bias, to maximize reproducibility and detection sensitivity, with the final aim to find relevant, specific and robust biomarkers should be addressed.
All these difficulties can be addressed only by substantial reduction in sample complexity and the application of a rigorous standardization program of the entire analytical process. This involves a fully operational and calibrated instrument and the use of suitable QC samples, similar in nature and complexity to the studied samples.
Indeed, the use of relevant quality controls (QCs) is highly recommended and even mandatory in such applications. One of the most challenging aspects in studying body fluids metabolic profiles is the sample preparation which remains a laborious and time consuming task as it usually needs enrichment and purification before sequencing by MS--MS. Ideally, sample preparation methods should be high--throughput, reproducible and preserve quantitative information. In addition, they should avoid loss and dilution of samples as well as to be compatible with downstream analytic techniques. In order to enlarge dynamic range and thus metabolite coverage, several complementary techniques of preparation can be combined. The use of orthogonal techniques is also mandatory to provide valuable information for the identification of unknown metabolites.
Another important methodological source of artefacts is the data analysis of metabolite profiles. The data pre--processing (calibration, baseline correction, normalization, peak detection and peak alignment) represents a key step for metabolomic analysis [41] .
Besides the instrumentation and the methodologies related to chromatography--mass spectrometry analysis, the nature, quality and number of clinical samples to process and statistical data treatment are also key elements to be considered for any metabolomic approaches.
Conclusions
Taking into account herein and previously described recommendations, metabolomic approaches offer very exciting opportunities to discover not only diagnostic, but prognostic and also mechanistic markers for a number of major diseases. This could lead to the identification of new targets and then new drugs with original modes of action. It is also expected that the ability to identify markers of drug toxicity/efficacy will significantly accelerate drug discovery and help define the appropriate clinical plan.
However, some challenges still remain, as for all other "omic" approaches, due in part to the complexity and the wide dynamic range of the samples. Sample fractionation and/or enrichment procedure will certainly be the solution to visualise the deep metabolome.
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